Jones JL - Search Results

1

Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

Jarvis LB, Rainbow DB, Coppard V, Howlett SK, Georgieva Z, Davies JL, Mullay HK, Hester J, Ashmore T, Van Den Bosch A, Grist JT, Coles AJ, Mousa HS, Pluchino S, Mahbubani KT, Griffin JL, Saeb-Parsy K, Issa F, Peruzzotti-Jametti L, Wicker LS, Jones JL. Jarvis LB, et al. Among authors: jones jl. Commun Biol. 2021 Oct 14;4(1):1186. doi: 10.1038/s42003-021-02721-x. Commun Biol. 2021. PMID: 34650224 Free PMC article.

2

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. Coles AJ, et al. J Neurol. 2006 Jan;253(1):98-108. doi: 10.1007/s00415-005-0934-5. Epub 2005 Jul 27. J Neurol. 2006. PMID: 16044212

3

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Cox AL, et al. Among authors: jones jl. Eur J Immunol. 2005 Nov;35(11):3332-42. doi: 10.1002/eji.200535075. Eur J Immunol. 2005. PMID: 16231285 Free article. Clinical Trial.

4

Campath-1H treatment of multiple sclerosis.

Jones JL, Coles AJ. Jones JL, et al. Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review.

5

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. Jones JL, et al. J Clin Invest. 2009 Jul;119(7):2052-61. doi: 10.1172/JCI37878. Epub 2009 Jun 22. J Clin Invest. 2009. PMID: 19546505 Free PMC article.

6

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. Thompson SA, et al. Among authors: jones jl. J Clin Immunol. 2010 Jan;30(1):99-105. doi: 10.1007/s10875-009-9327-3. Epub 2009 Sep 10. J Clin Immunol. 2010. PMID: 19763798

7

Spotlight on alemtuzumab.

Jones JL, Coles AJ. Jones JL, et al. Int MS J. 2009 Sep;16(3):77-81. Int MS J. 2009. PMID: 19878629 Review.

8

New treatment strategies in multiple sclerosis.

Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.

9

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Jones JL, et al. Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21. Brain. 2010. PMID: 20659956 Clinical Trial.

10

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.

Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Hill-Cawthorne GA, et al. Among authors: jones jl. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5. J Neurol Neurosurg Psychiatry. 2012. PMID: 22056965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

783 results

Search Page